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The appreciation of the substantial influence of biologi-
cal variation (BV) on laboratory testing and interpreta-
tion of laboratory results has represented a milestone in 
the history of laboratory medicine. It has paved the way 
for a wide series of studies aimed to accurately define the 
components of BV, set analytical quality specifications 
and related goals for internal quality control and exter-
nal quality assessment programs, along with specific 
criteria for data interpretation, including the reference 
change value (RCV) [1–3]. The unquestionable importance 
of quality specifications based on BV in the hierarchy of 
models defined in the Stockholm Conference in 1999 [4, 5] 
represented a breakthrough in promoting the generation 
and application of data on BV. This issue has been for long 
recognized in Clinical Chemistry and Laboratory Medicine 
as an essential concept for defining the appropriateness of 
reference values for specific constituents, and for support-
ing the adoption of RCV in the interpretation of data from 
serial measurements [6–16]. In this issue of the journal, we 
publish an article about structure and criteria used for the 
generation of the BV database [17] along with a comment-
ing Editorial, which are aimed to update our knowledge in 
this field and encouraging the revision and update of BV 
database, to reassure that the information is prominently 
evidence-based [18].
A number of problems are increasingly recognized 
as a source of debate and concern. First, in an era of 
global harmonization, mystification should be prevented 
in the broad range of terms and symbols used to define 
the components of BV [19]. Therefore, we recognize and 
support the recent proposition by Simundic et al. to adopt 
a consistent and harmonized use of terms and symbols as 
follows [20]:
 – CVI: within-subject biological variation (variation 
within a single individual estimated as a pooled vari-
ation from a group of individuals);
 – CVG: between-subject biological variation (varia-
tion between the central tendencies of a group of 
individuals);
 – CVA: analytical variation (analytical imprecision); 
should always be clarified, giving mode of derivation 
and type (such as reproducibility, reliability, or total) 
and number of analyses, runs, and time period;
 – RCV: reference change value (difference required for 
significance for 2 serial results from an individual); 
should always be accompanied by the formula used, 
namely, × ×1 2 1 22 2A I2 (CV CV ) ;Z  the Z-score should be 
defined to state the probability and whether unidi-
rectional or bidirectional differences were calculated; 
and
 – II: index of individuality (ratio of analytical and within-
subject to between-subject biological variation); 
should always be accompanied with the formula used 
for calculation: the preferred × 1 22 2A I G(CV CV ) /CV  or 
the now seemingly more usual CVI/CVG.
Accordingly, the journal will now recommend both 
authors and referees to comply with this harmonized use 
of terms and symbols, which are those originally used by 
Callum G. Fraser and adopted in the papers presented 
at the Stockholm Conference [3–5]. Further terms and 
symbols should, therefore, be viewed as simple mistakes 
or ‘deviation from the right way’.
Second, to guarantee the publication of valuable 
results, clinical investigations on BV should then rely on 
appropriate study designs, and in particular the reference 
population inclusion criteria should be carefully speci-
fied. Demographic characteristics, (e.g., age, sex and eth-
nicity), the clinical examination used to establish health 
in an individual, and subgroups analyses should be 
declared by authors. Therefore, we also support the sug-
gestion of Aarstand and colleagues to develop an interna-
tional standard for performing and reporting of studies on 
BV [18].
As a final consideration, studies should be based on 
a robust statistical analysis of data. This firstly entails the 
verification of data distribution, that can be either Gauss-
ian (i.e., normal) or non-Gaussian (i.e., non-normal). In 
the former instance, parametric analysis can be used [i.e., 
mean and standard deviation distribution, Pearson’s corre-
lation, Student’s t-test, and analysis of variance (ANOVA), 
etc]. As reported by Fraser and Harris [1], nested ANOVA is 
an efficient way to estimate CVI. Despite this method not 
being very sensitive to slightly deviation from normality, 
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it is highly sensitive to highly aberrant  observations. 
 Outliers can be detected by Cochran’s test and the Reed’s 
criterion, considering that if an assay is done in dupli-
cate and one measurement is aberrant, the advisable 
approach is to delete both of them. Moreover, data should 
be carefully inspected for homoscedasticity before apply-
ing ANOVA, as serious violation in homoscedasticity may 
result in biased estimates and in overestimated goodness 
of fit. In case of data showing a log-normal rather than a 
normal distribution, log-transformation should be per-
formed before the analyses as CVI and CVG can be calcu-
lated by back-transformation. Finally, for data that does 
meet neither normal nor log-normal distributions, a non-
parametric approach could be alternatively used, possibly 
evaluating the imprecision of estimates (i.e., median and 
percentile distribution, Spearman’s or Kendall’s correla-
tion, Mann-Whitney-Wilcoxon test, etc.) [21]. However, 
as up to now this latter topic has been only marginally 
studied, we suggest that clinical investigators should con-
centrate their future efforts to deal with BV calculation on 
non-normal distributed data.
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